Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs.
Maropitant is a neurokinin-1 inhibitor that acts to prevent and treat vomiting by blocking stimuli to the final common pathway in the emetic centre of the brain. The field efficacy and safety of a single oral dose of maropitant were investigated for the prevention of vomiting in dogs with a history of motion sickness resulting from transportation by car in two blinded, placebo-controlled studies. In an exploratory study designed as a two-way crossover trial with 17 dogs, 10 of the dogs given the placebo vomited during a car journey but only three of the dogs vomited under maropitant treatment. In a larger multicentred parallel design study, 69 of 105 dogs treated with the placebo vomited during the journey compared with 15 of 106 dogs treated with maropitant (P < 0.0001).
Benchaoui
H A
HA
Pfizer Animal Health, Veterinary Medicine Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ.
Siedek
E M
EM
De La Puente-Redondo
V A
VA
Tilt
N
N
Rowan
T G
TG
Clemence
R G
RG
D000818:Animals; D000932:Antiemetics / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D004311:Double-Blind Method; D005260:Female; D008297:Male; D009041:Motion Sickness / Q000517:prevention & control / Q000662:veterinary*; D011812:Quinuclidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000517:prevention & control / Q000662:veterinary*
D000932:Antiemetics; D011812:Quinuclidines; C518176:maropitant